See the DrugPatentWatch profile for Ranolazine
What drug class is ranolazine in?
Ranolazine is an antianginal medicine used to treat chronic (stable) angina. It is classified as a sodium (Na+) channel blocker—specifically, it inhibits the late inward sodium current in cardiac cells, which helps reduce abnormal electrical activity and improves heart muscle efficiency without mainly lowering heart rate or blood pressure. [1][2]
How does ranolazine work compared with beta blockers or nitrates?
Ranolazine’s primary effect is electrical/ionic: it reduces the late sodium current, which can indirectly improve calcium handling in cardiac cells. That differs from:
- Beta blockers, which primarily lower heart rate and contractility.
- Calcium channel blockers, which reduce heart workload mainly by affecting vascular tone/heart rate (depending on the drug).
- Nitrates, which mostly reduce preload by dilating veins and sometimes arteries. [1][2]
What conditions is ranolazine approved to treat?
Ranolazine is used for chronic (stable) angina, including situations where symptoms persist despite other antianginal therapies. [1]
Who should avoid or be cautious with ranolazine?
Ranolazine can interact with other medicines through drug-metabolism pathways, and it can affect the heart’s electrical properties (for example, QT-interval considerations). Patients should use it only when clinicians review their current medication list and risk factors. [1][3]
What do people usually mean by “ranolazine class” in prescribing?
Clinicians and formularies usually describe ranolazine by its therapeutic class (antianginal) and its pharmacologic mechanism (late sodium current inhibitor / sodium channel blocker). [1][2]
Sources
- https://www.drugs.com/ranolazine.html
- https://medlineplus.gov/druginfo/meds/a604009.html
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201526